ReviewMolecular medicine reports2021
Application of nanotechnology in drug delivery systems for respiratory diseases (Review).
Review in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).International journal of oncology · 2024Pooled it
- Inhalable Nanosystems for Bacterial Respiratory Infections: Addressing Pulmonary Barriers and Biofilm-Associated Challenges.International journal of nanomedicine · 2026Review
- Targeted biologic therapies and advanced drug delivery approaches in asthma management: a clinical perspective.Inflammopharmacology · 2025Review
- Nebulized Bacterioruberin/Astaxanthin-Loaded Nanovesicles: Antitumoral Activity and Beyond.International journal of molecular sciences · 2025Article
- Metallic, carbon-based, and polymeric nanomaterials: transforming dairy farming practices for sustainability.Food chemistry: X · 2025Review
- Next-generation pediatric care: nanotechnology-based and AI-driven solutions for cardiovascular, respiratory, and gastrointestinal disorders.World journal of pediatrics : WJP · 2025Review
- Recent Trends and Applications of Nanostructure-based Drug Delivery in Alleviating Chronic Obstructive Pulmonary Disease (COPD).Current drug delivery · 2025Review
- Green Chemically Synthesized Iron Oxide Nanoparticles-Chitosan Coatings for Enhancing Strawberry Shelf-Life.Polymers · 2024Article
- Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases.Journal of nanobiotechnology · 2024Review
- Recent Updates in Inhalable Drug Delivery System against Various Pulmonary Diseases: Challenges and Future Perspectives.Current drug delivery · 2024Review
- On the path to predicting immune responses in the lung: Modeling the pulmonary innate immune system at the air-liquid interface (ALI).European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2023Review
- Recent advances in nanoparticle applications in respiratory disorders: a review.Frontiers in pharmacology · 2023Review
- Polysaccharide-Based Nanomedicines Targeting Lung Cancer.Pharmaceutics · 2022Review
- Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs.Biomolecules · 2022Review
- Review
- Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery.Pharmaceutics · 2022Review
- Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.Current drug metabolism · 2022Article
- Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario.Current pharmaceutical design · 2022Review
- A scientometrics study of the nanomedicines assisted in respiratory diseases.Frontiers in bioengineering and biotechnology · 2022Article
- Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines.Saudi journal of biological sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory disease is a common disease with a high incidence worldwide, which is a serious threat to human health, and is considered a societal and economic burden. The application of nanotechnology in drug delivery systems has created new treatments for respiratory diseases. Within this context, the present review systematically introduced the physicochemical properties of nanoparticles (NPs); reviewed the current research status of different nanocarriers in the treatment of respiratory diseases, including liposomes, solid lipid nanocarriers, polymeric nanocarriers, dendrimers, inorganic nanocarriers and protein nanocarriers; and discussed the main advantages and limitations of therapeutic nanomedicine in this field. The application of nanotechnology overcomes drug inherent deficiencies to a certain extent, and provides unlimited potential for the development of drugs to treat respiratory diseases. However, most of the related research work is in the preclinical experimental stage and safety assessment is still a challenging task. Future studies are needed to focus on the performance modification, molecular mechanism and potential toxicity of therapeutic nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.